Emergent BioSolutions Reports Financial Results for Fourth Quarter and Full Year 2020
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- Wall St slips as steep oil prices stoke inflation concerns ahead of CPI
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Citi initiates UiPath coverage with Buy rating and $23 target
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- Harry and Meghan surprised by King Charles' letter on their status
- Wall St slips as steep oil prices stoke inflation concerns ahead of CPI
- Qualcomm to issue warrant to Amazon for up to 25M shares
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Emergent BioSolutions (EBS) PT Raised to $130 at Cantor Fitzgerald Following EPS
February 19, 2021 7:39 AM ESTCantor Fitzgerald analyst Brandon Folkes raised the price target on Emergent BioSolutions (NYSE: EBS) to $130.00 (from $110.00) while maintaining an Overweight rating.
The analyst commented, "Post 4Q20, we reiterate our Overweight rating and raise our 12-month price target to $130, from $110. EBS continues to be... More
Emergent BioSolutions (EBS) Tops Q4 EPS by 48c, Revenues Beat; Offers FY21 Revenue Guidance Above Consensus
February 18, 2021 4:20 PM ESTEmergent BioSolutions (NYSE: EBS) reported Q4 EPS of $3.67, $0.48 better than the analyst estimate of $3.19. Revenue for the quarter came in at $583 million versus the consensus estimate of $563.94 million.
Emergents financial and operational performance in 2020 reflects the impact we are making in addressing the... More
